Nomination Summary for Avastin (bevacizumab) (N21205)
Nominated Substances: Avastin (bevacizumab)
Nomination Date: 11/10/2011
Nominator: Private Individual
Rationale: Off-label use of bevacizumab for treating wet type macular degeneration by intravitreal injection has dramatically increased in opthalmology clinical practice. There is an urgent need to determine if this drug is carcinogenic, mutagenic or a reproductive toxicant, and thus whether it meets the NIOSH definition of a "hazardous drug" (http://www.cdc.gov/niosh/topics/hazdrug/) and should be added to the NIOSH hazardous drug list so that recommendations for safe handling and use can be implemented.
NTP Principles: not specified